Welcome to our dedicated page for Charlie S Holdin SEC filings (Ticker: CHUC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Charlie’s Holdings, Inc. (OTCQB: CHUC), a company operating in the premium vapor products space. These regulatory documents offer detailed information on the company’s financial condition, operations, and risk disclosures beyond what appears in press releases or marketing materials.
Charlie’s SEC filings include periodic reports such as Forms 10-K and 10-Q, which describe revenue, expenses, liquidity, and key business developments for its SBX, PACHA, and Pachamama 25K product lines. For example, the company has filed a Form 12b-25 (Notification of Late Filing) related to a Quarterly Report on Form 10-Q for the period ended September 30, 2025, explaining that additional time was needed for compilation and review to ensure adequate disclosure. Such filings help investors understand the timing and completeness of the company’s financial reporting.
Other SEC filings may cover topics such as capital structure changes, credit facilities, or material agreements, including arrangements that support SBX inventory purchases or the monetization of PMTA assets tied to PACHA synthetic nicotine products. Together, these documents outline how Charlie’s finances its operations, manages regulatory obligations, and accounts for income from strategic partnerships.
On Stock Titan, Charlie’s filings are updated as they are made available through the EDGAR system. AI-powered summaries help explain lengthy or technical sections of annual and quarterly reports, highlighting items such as segment performance, regulatory disclosures, and risk factors in more accessible language. Users can also review insider transaction reports on Form 4, if filed, to see reported purchases or sales of Charlie’s securities by officers, directors, or significant shareholders.
By combining real-time access to Charlie’s SEC filings with AI-generated explanations, this page is intended to make it easier to understand how the company reports its financial results, regulatory status, and key corporate actions over time.
Charlie’s Holdings, Inc. Chief Operating Officer Ryan Stump filed a Form 4 showing an open-market purchase of 250,000 shares of common stock on February 13, 2026 at $0.20 per share. After this transaction, he directly beneficially owns 2,351,968 common shares.
The filing also reports indirect beneficial ownership of 27,349,787 common shares held through the Ryan Stump Legacy Trust, in addition to his direct holdings.
Charlie's Holdings, Inc. president Henry Sicignano III reported buying additional common stock of the company. On February 13, 2026, he made an open-market purchase of 250,000 shares of Charlie's Holdings common stock at $0.20 per share.
Following this transaction, he directly beneficially owned 9,850,001 common shares. He also reported indirect beneficial ownership of 100,000 common shares held through an IRA, in addition to his direct holdings.
Charlie’s Holdings, Inc. Chief Financial Officer Matthew P. Montesano reported an open-market purchase of company stock. On 02/13/2026, he bought 100,000 shares of common stock at $0.20 per share. After this transaction, he directly owns 2,825,409 shares of Charlie’s Holdings common stock.
Charlie’s Holdings, Inc. director Michael D. King reported an open-market purchase of common stock. On 02/13/2026, he bought 500,000 shares at $0.2 per share. Following this transaction, he directly beneficially owns 6,750,001 shares of Charlie’s Holdings common stock.
Charlie's Holdings, Inc. entered into subscription agreements with investors on February 13, 2026 to sell 3,550,000 shares of common stock at
The company states that proceeds from this offering will be used for working capital purposes. The transaction was conducted as an unregistered sale of equity securities in reliance on Section 4(a)(2) of the Securities Act as a transaction not involving a public offering, and is documented in a form of subscription agreement attached as an exhibit.
Charlie's Holdings, Inc. director Edward Carmines reported an open-market purchase of common stock. On 02/13/2026, he bought 250,000 shares of Charlie's Holdings common stock at $0.20 per share. After this transaction, he directly owned 2,156,481 common shares and indirectly held 100,000 shares through a FamilyTrust.
Charlie's Holdings director reports insider share purchase
A director of Charlie's Holdings, Inc. bought 100,000 shares of the company’s common stock on 12/26/2025. The purchase was reported at a weighted average price of $0.276 per share, with individual trade prices ranging from $0.26 to $0.29. Following this transaction, the director now reports 100,000 shares held indirectly through a Family Trust and 1,906,481 shares held directly. This filing reflects the director increasing their economic exposure to Charlie's Holdings through both direct and indirect ownership.
Charlie's Holdings, Inc. reported an insider stock purchase by its president, Henry Sicignano, III. On December 17, 2025, he acquired 100,000 shares of common stock at a price of $0.21 per share. Following this transaction, he beneficially owns 9,600,001 shares directly and an additional 100,000 shares indirectly through an IRA, increasing his personal holdings in the company’s stock.
Charlie’s Holdings, Inc. (CHUC) reported a sharp improvement in results for the nine months ended September 30, 2025. Net product revenue rose to
Cash increased to
Strategically, Charlie’s is pushing Metatine-based SBX disposable vapes and other alternative alkaloid products, securing more than
Charlie’s Holdings, Inc. filed a Form 12b-25 to notify a late filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025. The company says it needs additional time to compile and review information to ensure adequate disclosure. It anticipates filing the Form 10-Q on or before the fifth calendar day following the prescribed due date.